Stock Scorecard



Stock Summary for UroGen Pharma Ltd (URGN) - $13.70 as of 6/30/2025 9:53:24 PM EST

Total Score

8 out of 30

Safety Score

37 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for URGN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for URGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for URGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for URGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for URGN (37 out of 100)

Stock Price Rating (Max of 10) 5
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for URGN

URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action - Contact Robbins LLP Before July 28 for Information - UroGen Pharma ( NASDAQ:URGN ) 7/1/2025 12:34:00 AM
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm - Fortrea Holdings ( NASDAQ:FTRE ) , Reckitt Benckiser Group ( OTC:RBGLY ) 6/24/2025 1:00:00 AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN - UroGen Pharma ( NASDAQ:URGN ) 6/23/2025 3:07:00 PM
Lowey Dannenberg Notifies UroGen Pharma Ltd. ( "UroGen" or the "Company" ) ( NASDQ: URGN ) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm 6/23/2025 2:34:00 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN - UroGen Pharma ( NASDAQ:URGN ) 6/18/2025 3:21:00 PM
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm - Fortrea Holdings ( NASDAQ:FTRE ) , Reckitt Benckiser Group ( OTC:RBGLY ) 6/17/2025 1:00:00 AM
Investors who lost money on UroGen Pharma Ltd. ( URGN ) should contact Levi & Korsinsky about pending Class Action - URGN - UroGen Pharma ( NASDAQ:URGN ) 6/16/2025 5:27:00 PM
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday - Advanced Micro Devices ( NASDAQ:AMD ) , AIRO Group Holdings ( NASDAQ:AIRO ) 6/16/2025 2:49:00 PM
URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud - Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline ( NASDAQ:URGN ) - UroGen Pharma ( NASDAQ:URGN ) 6/16/2025 12:17:00 PM
URGN SHAREHOLDERS: UroGen Pharma Ltd. Investors are Reminded of the Pending Securities Fraud Class Action - Contact BFA Law by July 28 Deadline ( NASDAQ:URGN ) - UroGen Pharma ( NASDAQ:URGN ) 6/14/2025 11:48:00 AM

Financial Details for URGN

Company Overview

Ticker URGN
Company Name UroGen Pharma Ltd
Country USA
Description N/A
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 13.70
Price 4 Years Ago 9.51
Last Day Price Updated 6/30/2025 9:53:24 PM EST
Last Day Volume 2,099,063
Average Daily Volume 5,258,823
52-Week High 18.15
52-Week Low 3.42
Last Price to 52 Week Low 300.58%

Valuation Measures

Trailing PE N/A
Industry PE 22.52
Sector PE 40.73
5-Year Average PE -4.62
Free Cash Flow Ratio 6.06
Industry Free Cash Flow Ratio 17.94
Sector Free Cash Flow Ratio 32.54
Current Ratio Most Recent Quarter 5.65
Total Cash Per Share 2.26
Book Value Per Share Most Recent Quarter -1.01
Price to Book Ratio 19.27
Industry Price to Book Ratio 35.01
Sector Price to Book Ratio 30.79
Price to Sales Ratio Twelve Trailing Months 6.77
Industry Price to Sales Ratio Twelve Trailing Months 123.25
Sector Price to Sales Ratio Twelve Trailing Months 35.57
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 46,107,500
Market Capitalization 631,672,750
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -24.09%
Reported EPS 12 Trailing Months -3.01
Reported EPS Past Year -0.92
Reported EPS Prior Year -3.23
Net Income Twelve Trailing Months -138,431,000
Net Income Past Year -126,874,000
Net Income Prior Year -102,244,000
Quarterly Revenue Growth YOY 7.80%
5-Year Revenue Growth 449.77%
Operating Margin Twelve Trailing Months -182.30%

Balance Sheet

Total Cash Most Recent Quarter 104,033,000
Total Cash Past Year 171,987,000
Total Cash Prior Year 95,002,000
Net Cash Position Most Recent Quarter -18,075,000
Net Cash Position Past Year 50,253,000
Long Term Debt Past Year 121,734,000
Long Term Debt Prior Year 98,551,000
Total Debt Most Recent Quarter 122,108,000
Equity to Debt Ratio Past Year -0.08
Equity to Debt Ratio Most Recent Quarter -0.61
Total Stockholder Equity Past Year -8,803,000
Total Stockholder Equity Prior Year -65,212,000
Total Stockholder Equity Most Recent Quarter -46,458,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -107,394,000
Free Cash Flow Per Share Twelve Trailing Months -2.33
Free Cash Flow Past Year -97,061,000
Free Cash Flow Prior Year -76,570,000

Options

Put/Call Ratio 2.10
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.89
MACD Signal 1.21
20-Day Bollinger Lower Band 4.92
20-Day Bollinger Middle Band 9.96
20-Day Bollinger Upper Band 15.00
Beta 0.40
RSI 66.90
50-Day SMA 11.60
150-Day SMA 12.18
200-Day SMA 11.70

System

Modified 6/28/2025 12:37:41 PM EST